Cargando…
Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis
Respiratory diseases are leading causes of death and disability in developing and developed countries. The burden of acute and chronic respiratory diseases has been rising throughout the world and represents a major problem in the public health system. Acute respiratory diseases include pneumonia, i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896872/ https://www.ncbi.nlm.nih.gov/pubmed/35280919 http://dx.doi.org/10.1016/j.jddst.2022.103219 |
_version_ | 1784663267254206464 |
---|---|
author | Ibarra-Sánchez, Luis Ángel Gámez-Méndez, Ana Martínez-Ruiz, Manuel Nájera-Martínez, Erik Francisco Morales-Flores, Brando Alan Melchor-Martínez, Elda M. Sosa-Hernández, Juan Eduardo Parra-Saldívar, Roberto Iqbal, Hafiz M.N. |
author_facet | Ibarra-Sánchez, Luis Ángel Gámez-Méndez, Ana Martínez-Ruiz, Manuel Nájera-Martínez, Erik Francisco Morales-Flores, Brando Alan Melchor-Martínez, Elda M. Sosa-Hernández, Juan Eduardo Parra-Saldívar, Roberto Iqbal, Hafiz M.N. |
author_sort | Ibarra-Sánchez, Luis Ángel |
collection | PubMed |
description | Respiratory diseases are leading causes of death and disability in developing and developed countries. The burden of acute and chronic respiratory diseases has been rising throughout the world and represents a major problem in the public health system. Acute respiratory diseases include pneumonia, influenza, SARS-CoV-2 and MERS viral infections; while chronic obstructive pulmonary disease (COPD), asthma and, occupational lung diseases (asbestosis, pneumoconiosis) and other parenchymal lung diseases namely lung cancer and tuberculosis are examples of chronic respiratory diseases. Importantly, chronic respiratory diseases are not curable and treatments for acute pathologies are particularly challenging. For that reason, the integration of nanotechnology to existing drugs or for the development of new treatments potentially benefits the therapeutic goals by making drugs more effective and exhibit fewer undesirable side effects to treat these conditions. Moreover, the integration of different nanostructures enables improvement of drug bioavailability, transport and delivery compared to stand-alone drugs in traditional respiratory therapy. Notably, there has been great progress in translating nanotechnology-based cancer therapies and diagnostics into the clinic; however, researchers in recent years have focused on the application of nanostructures in other relevant pulmonary diseases as revealed in our database search. Furthermore, polymeric nanoparticles and micelles are the most studied nanostructures in a wide range of diseases; however, liposomal nanostructures are recognized to be some of the most successful commercial drug delivery systems. In conclusion, this review presents an overview of the recent and relevant research in drug delivery systems for the treatment of different pulmonary diseases and outlines the trends, limitations, importance and application of nanomedicine technology in treatment and diagnosis and future work in this field. |
format | Online Article Text |
id | pubmed-8896872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88968722022-03-07 Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis Ibarra-Sánchez, Luis Ángel Gámez-Méndez, Ana Martínez-Ruiz, Manuel Nájera-Martínez, Erik Francisco Morales-Flores, Brando Alan Melchor-Martínez, Elda M. Sosa-Hernández, Juan Eduardo Parra-Saldívar, Roberto Iqbal, Hafiz M.N. J Drug Deliv Sci Technol Article Respiratory diseases are leading causes of death and disability in developing and developed countries. The burden of acute and chronic respiratory diseases has been rising throughout the world and represents a major problem in the public health system. Acute respiratory diseases include pneumonia, influenza, SARS-CoV-2 and MERS viral infections; while chronic obstructive pulmonary disease (COPD), asthma and, occupational lung diseases (asbestosis, pneumoconiosis) and other parenchymal lung diseases namely lung cancer and tuberculosis are examples of chronic respiratory diseases. Importantly, chronic respiratory diseases are not curable and treatments for acute pathologies are particularly challenging. For that reason, the integration of nanotechnology to existing drugs or for the development of new treatments potentially benefits the therapeutic goals by making drugs more effective and exhibit fewer undesirable side effects to treat these conditions. Moreover, the integration of different nanostructures enables improvement of drug bioavailability, transport and delivery compared to stand-alone drugs in traditional respiratory therapy. Notably, there has been great progress in translating nanotechnology-based cancer therapies and diagnostics into the clinic; however, researchers in recent years have focused on the application of nanostructures in other relevant pulmonary diseases as revealed in our database search. Furthermore, polymeric nanoparticles and micelles are the most studied nanostructures in a wide range of diseases; however, liposomal nanostructures are recognized to be some of the most successful commercial drug delivery systems. In conclusion, this review presents an overview of the recent and relevant research in drug delivery systems for the treatment of different pulmonary diseases and outlines the trends, limitations, importance and application of nanomedicine technology in treatment and diagnosis and future work in this field. Elsevier B.V. 2022-04 2022-03-05 /pmc/articles/PMC8896872/ /pubmed/35280919 http://dx.doi.org/10.1016/j.jddst.2022.103219 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ibarra-Sánchez, Luis Ángel Gámez-Méndez, Ana Martínez-Ruiz, Manuel Nájera-Martínez, Erik Francisco Morales-Flores, Brando Alan Melchor-Martínez, Elda M. Sosa-Hernández, Juan Eduardo Parra-Saldívar, Roberto Iqbal, Hafiz M.N. Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis |
title | Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis |
title_full | Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis |
title_fullStr | Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis |
title_full_unstemmed | Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis |
title_short | Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis |
title_sort | nanostructures for drug delivery in respiratory diseases therapeutics: revision of current trends and its comparative analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896872/ https://www.ncbi.nlm.nih.gov/pubmed/35280919 http://dx.doi.org/10.1016/j.jddst.2022.103219 |
work_keys_str_mv | AT ibarrasanchezluisangel nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT gamezmendezana nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT martinezruizmanuel nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT najeramartinezerikfrancisco nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT moralesfloresbrandoalan nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT melchormartinezeldam nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT sosahernandezjuaneduardo nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT parrasaldivarroberto nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis AT iqbalhafizmn nanostructuresfordrugdeliveryinrespiratorydiseasestherapeuticsrevisionofcurrenttrendsanditscomparativeanalysis |